Overview A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL) Status: Recruiting Trial end date: 2022-12-01 Target enrollment: Participant gender: Summary The objective of this study is to evaluate the efficacy of TQ-B3525 in patients with relapsed / refractory follicular lymphoma. Phase: Phase 2 Details Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.